Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.015 CAD | -62.50% | -62.50% | -25.00% |
Valuation
Fiscal Period: April | 2022 | 2023 |
---|---|---|
Capitalization 1 | 4.056 | 1.021 |
Enterprise Value (EV) 1 | 4.02 | 1.067 |
P/E ratio | -3.68 x | -0.68 x |
Yield | - | - |
Capitalization / Revenue | - | - |
EV / Revenue | - | - |
EV / EBITDA | -3.75 x | -0.98 x |
EV / FCF | 134,185,866 x | -11,881,452 x |
FCF Yield | 0% | -0% |
Price to Book | -116 x | -1.09 x |
Nbr of stocks (in thousands) | 7,115 | 34,033 |
Reference price 2 | 0.5700 | 0.0300 |
Announcement Date | 29/08/22 | 27/10/23 |
Income Statement Evolution (Annual data)
Fiscal Period: April | 2021 | 2022 | 2023 |
---|---|---|---|
Net sales | - | - | - |
EBITDA 1 | -0.6725 | -1.073 | -1.084 |
EBIT 1 | -0.7012 | -1.164 | -1.175 |
Operating Margin | - | - | - |
Earnings before Tax (EBT) 1 | -0.7346 | -5.657 | -1.491 |
Net income 1 | -0.7346 | -5.654 | -1.487 |
Net margin | - | - | - |
EPS 2 | -0.0212 | -0.1548 | -0.0438 |
Free Cash Flow | - | 0.03 | -0.0898 |
FCF margin | - | - | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 16/03/22 | 29/08/22 | 27/10/23 |
Balance Sheet Analysis
Fiscal Period: April | 2021 | 2022 | 2023 |
---|---|---|---|
Net Debt 1 | - | - | 0.05 |
Net Cash position 1 | 0.63 | 0.04 | - |
Leverage (Debt/EBITDA) | - | - | -0.0424 x |
Free Cash Flow | - | 0.03 | -0.09 |
ROE (net income / shareholders' equity) | - | -1,106% | 271% |
ROA (Net income/ Total Assets) | - | -86.1% | -265% |
Assets 1 | - | 6.563 | 0.5619 |
Book Value Per Share 2 | 0.0300 | -0 | -0.0300 |
Cash Flow per Share 2 | 0.0200 | 0 | 0 |
Capex 1 | 0.55 | - | - |
Capex / Sales | - | - | - |
Announcement Date | 16/03/22 | 29/08/22 | 27/10/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-25.00% | 526K | |
+39.25% | 53.67B | |
+33.67% | 38.86B | |
-7.72% | 38.76B | |
-10.77% | 27.27B | |
+12.46% | 25.91B | |
-18.03% | 20.29B | |
+34.63% | 12.78B | |
+29.29% | 12.18B | |
-2.90% | 11.96B |
- Stock Market
- Equities
- NIRV Stock
- Financials Nirvana Life Sciences Inc.